Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Österreich)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 740.2 USD | +0.61% |
|
+10.86% | +26.97% |
| Feb. 09 | S&P 500 Posts Fifth Consecutive Weekly Gain, Tops 5,000 First Time as Earnings Top Expectations | MT |
| Feb. 09 | Eli Lilly and Company Enters into an Underwriting Agreement | CI |
Financials (USD)
| Sales 2023 | 34.12B | Sales 2024 * | 41.38B | Capitalization | 666B |
|---|---|---|---|---|---|
| Net income 2023 | 5.24B | Net income 2024 * | 11.01B | EV / Sales 2023 | 15.4 x |
| Net Debt 2023 * | 14.68B | Net Debt 2024 * | 14.8B | EV / Sales 2024 * | 16.4 x |
| P/E ratio 2023 |
101
x | P/E ratio 2024 * |
60.7
x | Employees | 39,000 |
| Yield 2023 |
0.78% | Yield 2024 * |
0.7% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +0.61% | ||
| 1 week | +10.86% | ||
| Current month | +14.65% | ||
| 1 month | +18.33% | ||
| 3 months | +25.17% | ||
| 6 months | +40.65% | ||
| Current year | +26.97% |
1 week
682.53
745.70
1 month
612.70745.70
Current year
579.05745.70
1 year
309.20745.70
3 years
178.58745.70
5 years
101.36745.70
10 years
52.89745.70
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 13-09-30 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 64 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 19 M€ | +2.97% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-02-09 | 740.2 | +0.61% | 2,833,894 |
| 24-02-08 | 735.7 | +1.42% | 4,636,885 |
| 24-02-07 | 725.4 | +2.89% | 5,797,966 |
| 24-02-06 | 705 | -0.17% | 8,199,902 |
| 24-02-05 | 706.2 | +5.77% | 7,602,392 |
Delayed Quote Nyse, February 09, 2024 at 04:00 pm EST
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (46.6%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (20.3%);
- immunology diseases (11.8%);
- neurology (6.7%): primarily drugs used in treating depression and schizophrenia;
- other (14.6%).
Net sales are distributed geographically as follows: the United States (59.4%), Europe (16.9%), Japan (8.3%), China (5.9%) and other (9.5%).
Sector
Pharmaceuticals
Calendar
2024-02-13
- Ex-dividend day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
740.2
USD
Average target price
726.1
USD
Spread / Average Target
-1.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.97% | 666 B $ | |
| +19.17% | 536 B $ | |
| +0.01% | 377 B $ | |
| +15.07% | 318 B $ | |
| +12.33% | 307 B $ | |
| -8.02% | 207 B $ | |
| +4.05% | 206 B $ | |
| -7.92% | 191 B $ | |
| -4.27% | 156 B $ | |
| -3.63% | 117 B $ |
